• To determine and compare the pharmacokinetics (PK) of 3 doses of 25 mg Androxal in elderly healthy adult male subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Unnamed facility
Miami, Florida, United States
Pharmacokinetics - The Cmax will be calculated.
Time frame: 4 days
Pharmacokinetics - The Tmax will be calculated.
Time frame: 4 days
Pharmacokinetics - The AUC0-24 will be calculated.
Time frame: 4 days
Pharmacokinetics - the AUC0-∞ will be calculated.
Time frame: 4 days
Pharmacokinetics - The t½ will be calculated.
Time frame: 4 days
Safety - Incidence of adverse events
Time frame: 4 days
Safety -Mean change from baseline in laboratory values
Time frame: 4 days
Safety - Mean change from baseline in vital signs
Time frame: 4 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.